In the B-cell precursor acute lymphoblastic leukemia (BCP-ALL), IKZF1 deletions are linked to increased relapse risk [37,38], while in chronic lymphocytic leukemia (CLL), IKZF3 and TP53 have been identified as relapse drivers displaying increased mutation frequency in relapsed samples after immunochemotherapy [39]. The gene discussed is IKZF1; the disease is B-cell chronic lymphocytic leukemia.